Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Arm Study to Investigate the Efficacy and Safety of Inhaled Laninamivir Octanoate TwinCaps Dry Powder Inhaler in Adults With Symptomatic Influenza A or B Infection

Next Previous
X
Search
Trial Profile

A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Arm Study to Investigate the Efficacy and Safety of Inhaled Laninamivir Octanoate TwinCaps Dry Powder Inhaler in Adults With Symptomatic Influenza A or B Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Laninamivir (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Therapeutic Use
  • Acronyms IGLOO
  • Sponsors Biota Pharmaceuticals

    • Most Recent Events

    • 03 Aug 2017 This trial has been discontinued in Belgium.
    • 09 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Aug 2014 Status changed from recruiting to active, no longer recruiting, according to a Biota Pharmaceuticals media release, which reported 639 patients were enrolled between June 2013 and April 2014.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top